Progyny Inc. (PGNY)
NASDAQ (NGS) NASDAQ (NGS) Primary 
Progyny, Inc. (PGNY) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Progyny, Inc. (PGNY) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Progyny: Transitional Headwinds Hide An Undervalued Platform
Progyny (PGNY) is undervalued at 9.3x forward P/E, with strong cash flow, expanding margins, and a resilient business model post-Amazon client loss. Headline FY26 growth appears muted (5.1%–9%) due to tough comps, but underlying growth excluding Amazon is 9.3–13.3%, with stable utilization rates near 1% and covered lives still expanding. PGNY's differentiated, outcome-focused platform, high retention, and buybacks (~15% share reduction in two years) support a robust medium-term investment case.
Progyny, Inc. (PGNY) Q4 2025 Earnings Call Transcript
Progyny, Inc. (PGNY) Q4 2025 Earnings Call Transcript
Progyny (PGNY) Q4 Earnings and Revenues Surpass Estimates
Progyny (PGNY) came out with quarterly earnings of $0.48 per share, beating the Zacks Consensus Estimate of $0.38 per share. This compares to earnings of $0.42 per share a year ago.
Compared to Estimates, Progyny (PGNY) Q4 Earnings: A Look at Key Metrics
The headline numbers for Progyny (PGNY) give insight into how the company performed in the quarter ended December 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Seeking Clues to Progyny (PGNY) Q4 Earnings? A Peek Into Wall Street Projections for Key Metrics
Besides Wall Street's top-and-bottom-line estimates for Progyny (PGNY), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2025.
Progyny, Inc. (PGNY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Progyny, Inc. (PGNY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Progyny, Inc. (PGNY) Soars to 52-Week High, Time to Cash Out?
Progyny (PGNY) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Progyny, Inc. (PGNY) Hits Fresh High: Is There Still Room to Run?
Progyny (PGNY) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Progyny (PGNY) Upgraded to Buy: Here's What You Should Know
Progyny (PGNY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Is Progyny (PGNY) a Solid Growth Stock? 3 Reasons to Think "Yes"
Progyny (PGNY) possesses solid growth attributes, which could help it handily outperform the market.
Progyny: Growth Has Returned (Rating Upgrade)
Progyny (PGNY) surges after strong Q3 earnings, robust client growth, and a $200M share buyback, signaling renewed momentum and market confidence. PGNY overcame Amazon's departure by adding new clients, achieving near 100% renewal rates, and accelerating revenue growth across both business segments. Analyst upgrades, insider buying, and secular tailwinds—like rising infertility and delayed childbirth—support a bullish outlook and reinforce the company's competitive moat.
